Computer-assisted immunohistochemical (IHC) scoring of erb-b2 receptor tyrosine kinase 2 (HER2) protein expression in breast cancer

被引：0
|
作者：
Marati, V. [1 ]
Inge, L. [1 ]
Jimenez, J. [1 ]
Chen, C. [1 ]
Miri, M. S. [1 ]
Zuiderveld, K. [1 ]
Martin, J. [1 ]
Lopez, B. [1 ]
Kapadia, M. [1 ]
Khojasteh, M. [1 ]
Luu, D. [1 ]
Ranger-Moore, J. [1 ]
Guetter, C. [1 ]
机构：
[1] Global Med Affairs, Roche Diagnost Solut, Irvine, CA USA
来源：
VIRCHOWS ARCHIV | 2021年 / 479卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
PS-14-002
引用
收藏
页码：S132 / S132
页数：1
相关论文
共 50 条
  • [21] Biased activation of the receptor tyrosine kinase HER2
    Claudia Catapano
    Johanna V. Rahm
    Marjan Omer
    Laura Teodori
    Jørgen Kjems
    Marina S. Dietz
    Mike Heilemann
    Cellular and Molecular Life Sciences, 2023, 80
  • [22] Biased activation of the receptor tyrosine kinase HER2
    Catapano, Claudia
    Rahm, Johanna V.
    Omer, Marjan
    Teodori, Laura
    Kjems, Jorgen
    Dietz, Marina S.
    Heilemann, Mike
    CELLULAR AND MOLECULAR LIFE SCIENCES, 2023, 80 (06)
  • [23] Assessment of Reproducibility of HER2 IHC Scoring in a HER2-low Breast Cancer Enriched Cohort among Breast Subspecialized Pathologists
    Karakas, Cansu
    Tyburski, Haley
    Turner, Bradley
    Wang, Xi
    Schiffhauer, Linda
    Katerji, Hani
    Liu, Elena
    Hicks, David
    Zhang, Huina
    LABORATORY INVESTIGATION, 2023, 103 (03) : S150 - S151
  • [24] Erb-B2 receptor tyrosine kinase 2 knockdown inhibits retinoblastoma progression via Wnt/β-catenin signaling pathway in vitro
    Liu, B.
    Gao, T.
    Wu, H-Y
    Wan, M.
    JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS, 2021, 35 (01): : 209 - 214
  • [25] Concordance of HER2 IHC Scoring in HER2-Low Breast Biopsy and Subsequent Excision Specimens
    Finkelman, Brian
    Zhang, Huina
    Tyburski, Haley
    Karakas, Cansu
    Schiffhauer, Linda
    Chen, Jack
    Wang, Xi
    Katerji, Hani
    Hicks, David
    Turner, Bradley
    LABORATORY INVESTIGATION, 2023, 103 (03) : S131 - S131
  • [26] Neratinib, an irreversible pan erB receptor tyrosine kinase inhibitor active for advanced HER2+breast cancer
    H Cortés-Funes
    C Mendiola
    L Manso
    E Ciruelos
    Breast Cancer Research, 11
  • [27] Neratinib, an irreversible pan erB receptor tyrosine kinase inhibitor active for advanced HER2+ breast cancer
    Cortes-Funes, H.
    Mendiola, C.
    Manso, L.
    Ciruelos, E.
    BREAST CANCER RESEARCH, 2009, 11 : S8 - S8
  • [28] Differential response of HER2 positive breast cancer based on HER2 protein expression level
    Atallah, N. M.
    Toss, M. S.
    Al Saleem, M.
    Green, A. R.
    Mongan, N. P.
    Rakha, E. A.
    JOURNAL OF PATHOLOGY, 2023, 261 : S9 - S9
  • [29] Current updates on EGFR and HER2 tyrosine kinase inhibitors for the breast cancer
    Prasad Sanjay Dhiwar
    Gurubasavaraja Swamy Purwarga Matada
    Nulgumnalli Manjunathaiah Raghavendra
    Abhishek Ghara
    Ekta Singh
    Nahid Abbas
    Ganesh Sakaram Andhale
    Ganesh Prasad Shenoy
    Pujan Sasmal
    Medicinal Chemistry Research, 2022, 31 : 1401 - 1413
  • [30] Current updates on EGFR and HER2 tyrosine kinase inhibitors for the breast cancer
    Dhiwar, Prasad Sanjay
    Matada, Gurubasavaraja Swamy Purwarga
    Raghavendra, Nulgumnalli Manjunathaiah
    Ghara, Abhishek
    Singh, Ekta
    Abbas, Nahid
    Andhale, Ganesh Sakaram
    Shenoy, Ganesh Prasad
    Sasmal, Pujan
    MEDICINAL CHEMISTRY RESEARCH, 2022, 31 (09) : 1401 - 1413
12345